Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Briefs: OIG News; Next-Gen Sequencing Guidance

This article was originally published in The Gray Sheet

Executive Summary

HHS Office of Inspector General finds Medicare pays more than double what private insurers pay for vacuum erection systems , and recommends CMS review its error-rate reduction plans for claims administration contractors. Baltimore-based group to develop guidance to evaluate next-gen sequencing-based tests for cancer. More reimbursement news.

You may also be interested in...



Medicare Durable Equipment Cuts Will Deepen In Next Round Of Competitive Bidding

Starting July 1, Medicare plans to pay 45 percent less than current fee-schedule rates for eight categories of DMEPOS in 91 cities, and 72 percent less nationwide for diabetes products.

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs

There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel